Uni-Pex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 27-12-2024
- Paid Up Capital ₹ 5.00 M
as on 27-12-2024
- Company Age 25 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.75 Cr
as on 27-12-2024
- Satisfied Charges ₹ 20.00 Cr
as on 27-12-2024
- Revenue 98.35%
(FY 2022)
- Profit 17.88%
(FY 2022)
- Ebitda -150.89%
(FY 2022)
- Net Worth 7.42%
(FY 2022)
- Total Assets 57.15%
(FY 2022)
About Uni-Pex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.75 Cr. The company has closed loans amounting to ₹20.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Madan Bansal and Jagdish Bansal serve as directors at the Company.
- CIN/LLPIN
U24231DL1999PTC098759
- Company No.
098759
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Uni-Pex Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madan Bansal  | Director | 10-Mar-1999 | Current |
| Jagdish Bansal | Director | 10-Mar-1999 | Current |
Financial Performance of Uni-Pex Pharmaceuticals.
Uni-Pex Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 98.35% increase. The company also saw a substantial improvement in profitability, with a 17.88% increase in profit. The company's net worth moved up by a moderate rise of 7.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uni-Pex Pharmaceuticals?
In 2023, Uni-Pex Pharmaceuticals had a promoter holding of 72.33% and a public holding of 27.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maxtar Bio-Genics Private LimitedActive 21 years 5 monthsMadan Bansal and Jagdish Bansal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 23 Nov 2021 | ₹1.75 Cr | Open |
Hdfc Bank Limited Creation Date: 14 Sep 2022 | ₹20.00 Cr | Satisfied |
How Many Employees Work at Uni-Pex Pharmaceuticals?
Unlock and access historical data on people associated with Uni-Pex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uni-Pex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uni-Pex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
